Gold prices steady ahead of Fed decision; weekly weakness noted
IRVINE, Calif. - Medical (TASE:BLWV) technology company Masimo Corporation (NASDAQ:MASI) reported first quarter earnings that beat analyst expectations, but shares fell 4% in after-hours trading as full-year guidance came in below estimates.
Masimo posted adjusted earnings per share of $1.36 for Q1 2025, surpassing the analyst consensus of $1.21. Revenue rose 10% YoY to $372 million, also topping expectations of $367.84 million.
However, the company’s outlook for the full year 2025 disappointed investors. Masimo now expects adjusted EPS of $4.80 to $5.15, below the $5.25 analysts were projecting. The revenue forecast of $1.5 billion to $1.53 billion was roughly in line with the $1.517 billion consensus.
CEO Katie Szyman highlighted the strong Q1 performance, stating, "Our first quarter results clearly demonstrate the earnings power of our core business as we delivered double-digit revenue growth and exceptional earnings growth."
The company noted its guidance now includes the impact of new tariffs before any mitigation efforts. Masimo said it has developed mitigation plans and will continue to reassess as the tariff situation evolves.
For Q1, Masimo reported GAAP net income from continuing operations of $47.2 million, or $0.86 per diluted share. This compares to $32.1 million, or $0.59 per share, in the same quarter last year.
The company’s healthcare segment saw non-GAAP constant currency revenue growth of 10.5% YoY. Meanwhile, Masimo recorded a $218 million loss from discontinued operations related to its non-healthcare consumer audio business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.